The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.